Comparative Pharmacology
Head-to-head clinical analysis: UVADEX versus VYLOY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: UVADEX versus VYLOY.
UVADEX vs VYLOY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Uvadex, when combined with UVA light, intercalates into DNA and upon UVA activation forms covalent cross-links with pyrimidine bases, thereby inhibiting DNA synthesis and inducing apoptosis in activated T-cells.
VYLOY (zolbetuximab-clzb) is a chimeric IgG1 monoclonal antibody that binds to claudin 18.2 (CLDN18.2), a tight junction protein expressed on the surface of gastric cancer cells. Binding induces antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to tumor cell death.
200 mcg/mL solution administered via intravenous injection 0.017 mL/kg (3.4 mcg/kg) 30 minutes prior to each photopheresis treatment, given on two consecutive days every 2–4 weeks.
VYLOY (zolbetuximab-clzb) is administered intravenously at a dose of 800 mg every 2 weeks following a loading dose of 1200 mg on day 1 of cycle 1.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours (range 8-20 hours) following intravenous administration; clinically, this supports daily dosing schedules.
Approximately 2.2 hours (terminal elimination half-life); clinical context: supports twice-weekly dosing schedule.
Primarily renal excretion of unchanged drug (approximately 70% within 24 hours) and metabolites; minor fecal elimination (<10%).
Primarily hepatobiliary excretion into feces; minimal renal elimination (<1% unchanged in urine).
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent